title: RETRACTED: Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.
abstract: This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/locate/withdrawalpolicy).
  
  This article has been retracted at the request of the Editor-in-Chief
  
  Concern has been raised about the duplication of the β-Actin protein blot in the western blots that are in Figure 3A and Figure 4C. The authors have been asked to provide an acceptable explanation for this and – after initial denial and being presented with an independent evaluation noted that the western blot for β-Actin in Figure 3A was erroneously uploaded as a partial duplication of the β-Actin western blot in Figure 4C. According to the authors, this mistake was due to the fact that both Figure 3A and Figure 4C are representing the same experiment with only different protein species presented in the two Figures and with the loading control β-Actin that is presented in both Figures.
  
  The Editor-in-Chief of the journal therefore feels that the findings of the manuscript cannot be relied upon and that the article needs to be retracted.
  
  All authors agree with this retraction and deeply regret these errors and apologize to the editorial board and readers for any inconvenience caused.
authors.affiliation: Oncologia Medica, Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale F. Magrassi e A. Lanzara, Seconda Università degli Studi di Napoli, Via S. Pansini 5, 80131 Naples, Italy.
authors.forename: Floriana
authors.initials: F
authors.lastname: Morgillo
authors.forename: Elena
authors.initials: E
authors.lastname: D'Aiuto
authors.forename: Teresa
authors.initials: T
authors.lastname: Troiani
authors.forename: Erika
authors.initials: E
authors.lastname: Martinelli
authors.forename: Tina
authors.initials: T
authors.lastname: Cascone
authors.forename: Raffaele
authors.initials: R
authors.lastname: De Palma
authors.forename: Michele
authors.initials: M
authors.lastname: Orditura
authors.forename: Ferdinando
authors.initials: F
authors.lastname: De Vita
authors.forename: Fortunato
authors.initials: F
authors.lastname: Ciardiello
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001897:Boronic Acids / Q000494:pharmacology*; D000069286:Bortezomib; D002289:Carcinoma, Non-Small-Cell Lung / Q000503:physiopathology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000235:genetics; D000069347:Erlotinib Hydrochloride; D005260:Female; D000077156:Gefitinib; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011719:Pyrazines / Q000494:pharmacology*; D011799:Quinazolines / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D047428:Protein Kinase Inhibitors; D011719:Pyrazines; D011799:Quinazolines; D000069286:Bortezomib; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib